Auscann Group Holdings Ltd banner

Auscann Group Holdings Ltd
ASX:AC8

Watchlist Manager
Auscann Group Holdings Ltd Logo
Auscann Group Holdings Ltd
ASX:AC8
Watchlist
Price: 0.04 AUD -4.76% Market Closed
Market Cap: AU$17.6m

Auscann Group Holdings Ltd
Other

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Auscann Group Holdings Ltd
Other Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other CAGR 3Y CAGR 5Y CAGR 10Y
Auscann Group Holdings Ltd
ASX:AC8
Other
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Recce Pharmaceuticals Ltd
ASX:RCE
Other
-AU$186.1k
CAGR 3-Years
N/A
CAGR 5-Years
36%
CAGR 10-Years
N/A
Mayne Pharma Group Ltd
ASX:MYX
Other
AU$3.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Neuren Pharmaceuticals Ltd
ASX:NEU
Other
-AU$37k
CAGR 3-Years
-164%
CAGR 5-Years
49%
CAGR 10-Years
-12%
C
Clarity Pharmaceuticals Ltd
ASX:CU6
Other
-AU$193.4k
CAGR 3-Years
67%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vita Life Sciences Ltd
ASX:VLS
Other
AU$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Auscann Group Holdings Ltd
Glance View

Market Cap
17.6m AUD
Industry
Pharmaceuticals

AusCann Group Holdings Ltd. engages in development, production, and distribution of cannabinoid-based medicines within Australia and internationally. The company is headquartered in Perth, Western Australia. The firm focuses on providing healthcare professionals and veterinarians with pharmaceutical and nutraceutical products to support the treatment of their patients. Its controlled-dose technology platform, Neuvis, is for delivering cannabinoids to human patients through CannPal Animal Therapeutics Pty Ltd. DermaCann is its lead cannabidiol (CBD) derived nutraceutical in development for healthy skin and immune function in dogs with dermatological conditions. CPAT-01 is a liquid, oral veterinary medicine containing tetrahydrocannabinol (THC) and CBD whole plant extracts in a combined ratio to cure pain and inflammation in dogs. CPAT-01 is in Phase II clinical trials. AusCann Operations Pty Ltd and CannPal Animal Therapeutics Limited are its subsidiaries.

AC8 Intrinsic Value
Not Available

See Also

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett